Industry consolidation and cross-border deals are attractive opportunities for the firm in China, says Warburg managing director Min Fang.
Big pharma debt loads are spurring non-core divestment and creating opportunities for private equity carve-outs, GTCR managing director Sean Cunningham tells PHI.
Competition in healthcare deals in Asia is increasing along with demand in speciality healthcare, according to TPG Growth partner Matthew Hobart.
European LPs aren’t the only ones concerned with environmental, social, and corporate governance issues – these days, US LPs are increasingly keen to know what buyout giant KKR is doing to be part of the solution, the firm’s ESG director Elizabeth Seeger says.
Healthcare and M&A specialist Richard Zall, a partner at New York-based law firm Proskauer Rose, says PE fund managers need to develop networks of advisors with specialised knowledge if they want to outmanoeuvre strategic buyers.
Abraaj regional head for MENA, Ahmed Badreldin, talks about how to consolidate in the region, IPO sentiment and growth plans.
As the healthcare sector continues to evolve, private equity dealflow should remain strong, according to Bain & Co partner Nirad Jain.
Private Healthcare Investor caught up with healthcare sector head John McKernan to discuss how the GP is playing sector trends in North America.
Sister publication Private Equity International spoke to Cinven partner and head of its healthcare team, Supraj Rajagopalan, about the current backdrop for the sector and the key issues to watch out for in 2016.
Frazier Healthcare Partners managing general partner for life sciences Jamie Topper talks about raising capital for the firm’s $262 million fund for cutting-edge biotech, and says that the cooling IPO market is nothing to fear.